▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Nova Eye Medical in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.24.
The current consensus among 0 polled investment analysts is to n/a stock in Nova Eye Medical. This rating has held steady since November 2020, when it changed from a Buy consensus rating.
Nova Eye Medical Limited designs, manufactures, distributes, and services medical equipment and devices to diagnose and treat eye diseases. The company offers iTrack, a surgical system for the reduction of intraocular pressure (IOP) in adult patients with openangle glaucoma; and 2RT, a proprietary laser technology to treat patients in early/intermediate age-related macular degeneration. It operates in Australia, the United States, Europe, the Middle East, Japan, rest of Asia, South America, and internationally. Nova Eye Medical Limited was incorporated in 1970 and is headquartered in Kent Town, Australia.